Skip to content
CancerIndex

Publication

Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.

Vasiliki Kostiou, Vijayalakshmi Chelliah, Piet H van der Graaf, Andrzej M Kierzek, Tasmin Farzana, Sham Mailankody, Eric M Jurgens

Clinical pharmacology and therapeuticsOct 1, 2026PMID 42364971doi:10.1002/cpt.70378 PMC13339306Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Oct 1, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20261001-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Despite promising outcomes in CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM), nearly all patients eventually relapse. Resistance and relapse may be driven by CAR T-cell and tumor-intrinsic factors. Here, we developed a mechanistic quantitative systems pharmacology (QSP) model of…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.